Dennis Heaney
Psychiatry · Edmond, OKNPI 1437868254
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 694 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 694 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$1K
- Alkermes, Inc.$826
- Takeda Pharmaceuticals U.S.A., Inc.$789
- Noven Therapeutics, LLC$757
- plus $6K from 22 others
What the payments were for
- Food & beverage$11,90599%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 93 | $1,461 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,352 |
| Axsome Therapeutics, Inc. | 68 | $1,034 |
| Alkermes, Inc. | 53 | $826 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $789 |
| Noven Therapeutics, LLC | 60 | $757 |
| Neurocrine Biosciences, Inc. | 52 | $740 |
| Johnson & Johnson | 33 | $737 |
| Otsuka America Pharmaceutical, Inc. | 54 | $714 |
| Ironshore Pharmaceuticals Inc. | 30 | $593 |
| Teva Pharmaceuticals USA, Inc. | 29 | $543 |
| Lundbeck LLC | 25 | $387 |
| Bausch Health US, LLC | 20 | $383 |
| Corium, LLC | 15 | $328 |
| Supernus Pharmaceuticals, Inc. | 15 | $300 |
| Idorsia Pharmaceuticals US Inc | 12 | $262 |
| Vanda Pharmaceuticals Inc. | 12 | $241 |
| Harmony Biosciences LLC | 6 | $142 |
| Braeburn Inc. | 5 | $110 |
| Indivior Inc. | 3 | $56 |
| Neos Therapeutics, LP | 3 | $55 |
| Merck | 3 | $51 |
| Lilly USA, LLC | 2 | $48 |
| Orexo US, Inc. | 2 | $29 |
| Almatica Pharma LLC | 1 | $22 |
| Noven Pharmaceuticals, Inc. | 1 | $19 |
| Sage Therapeutics, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$229
- SPRAVATO$141
- Austedo XR$123
- VRAYLAR$116
How this compares
$12,011 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 12 | $5,286 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $2,902 |
| Bupropion XlBupropion Hcl | 13 | $721 |
| Aripiprazole | 11 | $412 |
| Lamotrigine | 15 | $258 |
| Gabapentin | 15 | $245 |
| Pregabalin | 23 | $241 |
| Olanzapine | 14 | $230 |
| Trazodone Hcl | 14 | $168 |
| Alprazolam | 27 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckBelsomra | $51 | $5,28612 claims |
| Lilly USA, LLCOlanzapine | $48 | $23014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Edmond
- Jennifer MorrisEdmond$26K
- Shawn KhavariEdmond$11K
- Melanie BarrettEdmond$3K
- Shyvonne GrayEdmond$2K
- Robert MortonAda$1.9M
- Sarah LandTulsa$287K
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Charles LesterMuskogee$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.